Thioredoxin-1 Activation by Pterostilbene Protects Against Doxorubicin-Induced Hepatotoxicity via Inhibiting the NLRP3 Inflammasome

Background: Doxorubicin (DOX) has been widely used in cancer treatment. However, DOX can cause a range of significant side effects, of which hepatotoxicity is a common one, and therefore limits its clinical use. Pterostilbene (PTS) has been shown to exhibit anti-oxidant and anti-inflammatory effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Shiqing, Bai, Jie, Xu, Mingxi, Zhang, Longying, Wang, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043100/
https://www.ncbi.nlm.nih.gov/pubmed/35496300
http://dx.doi.org/10.3389/fphar.2022.841330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043100/
https://www.ncbi.nlm.nih.gov/pubmed/35496300
http://dx.doi.org/10.3389/fphar.2022.841330

Ejemplares similares